Biotech Digest – CLRB Reports Positive Results, TNDM Receives New Patent, DERM Inks New Deal

Cellectar Biosciences stock shot up as the company announced achieving overall survival of 22.5 months to date after a single dose infusion of 12.5mCi/m2 in patients with multiple myeloma.